Blue Trust Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 46.3% during the third quarter, ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Good Life Advisors LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 17.3% during the third ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

No matter what happens, investing in companies that will get through bear markets and perform well over the long run is ...

DBS analyst Nico Chen has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your ...